Andrew M. King

Andrew M. King

Auto-generated profile, based on publicly available information

Andrew M. King

Wayne State University School of Medicine

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2015 in Emergency Medicine Clinics of North America
Verified
Journal Article
Closed access
AKAndrew M. King
Andrew M. King
CACynthia K. Aaron
Cynthia K. Aaron

1 January 2018 in Current Hypertension Reports
Verified
Journal Article
Closed access
PDF file
AKAndrew King
Andrew King
MDMirjana Dimovska
Mirjana Dimovska
LBLuke Bisoski
Luke Bisoski

1 February 2021 in The American Journal of Emergency Medicine
Verified
Journal Article
Closed access
BMBrandon Marshall
Brandon Marshall
EMErin McGlynn
Erin McGlynn
AKAndrew King
Andrew King

23 October 2018 in Journal of Medical Toxicology
Verified
Journal Article
Closed access
PDF file
AKAndrew M. King
Andrew M. King
SDShooshan Danagoulian
Shooshan Danagoulian
MLMichael Lynch
Michael Lynch
NMNathan Menke
Nathan Menke
YMYijia Mu
Yijia Mu
APAnthony F. Pizon
Anthony F. Pizon

1 February 2019 in American Journal of Public Health
Verified
Journal Article
Closed access
AKAndrew King
Andrew King
DFDaniel Foley
Daniel Foley
CACynthia Arfken
Cynthia Arfken
CACynthia Aaron
Cynthia Aaron
LSLokman Sung
Lokman Sung
LHLeigh Hlavaty
Leigh Hlavaty
Objectives. To identify opioids associated with a spike in opioid-related mortality in Wayne County, Michigan, from July 2016 through February 2017. Methods. We reviewed records from the Wayne County Medical Examiner’s Office of 645 people who died because of accidental nonmedically prescribed opioid overdoses from July 2015 through July 2017. We analyzed basic demographics, locations of death, and all opioid toxicology results. Decedents who died in hospitals were excluded. Results. Of the 645 people who died because of nonmedically prescribed opioid overdoses, 65% were male and 63% were White, with an average age of 43 years. Carfentanil was detected in 129 (20%) cases. During the 8-month mortality spike, carfentanil was detected in 114 of 419 cases (average = 27.2%; range = 6.4%–45.2%). Substances most frequently detected with carfentanil included morphine (57%), 6-monoacetylmorphine (38%), fentanyl (43%), norfentanyl (33%), tetrahydrocannabinol (34%), and cocaine (29%). Conclusions. The Wayne County spike in mortality temporally corresponded with the detection of carfentanil and a proportional increase in opioid overdose deaths with detectable carfentanil. Public Health Implications. The abrupt decrease in carfentanil-detected mortality coincided with an announcement indicating an impending ban on fentanyl analogs from China, which suggests that source control is an effective countermeasure.

1 September 2023 in Oxford Medical Case Reports
Verified
Journal Article
Open access
PDF file
BYBrandtly Yakey
Brandtly Yakey
VVVarun Vohra
Varun Vohra
AMAmarilis Martin
Amarilis Martin
AKAndrew M King
Andrew M King
Antimuscarinic drug toxicity is a common pediatric emergency, which produces central and peripheral symptoms. Treatment of agitation and hyperactive antimuscarinic delirium, with first-line agents like cholinesterase inhibitors or benzodiazepines, is imperative to prevent severe toxicity. Intravenous physostigmine salicylate is a cholinesterase inhibitor that is commonly used to treat central antimuscarinic delirium. Its chemical structure facilitates crossing of the blood–brain barrier. Overlapping nationwide physostigmine and benzodiazepine shortages have prompted consideration of therapeutic alternatives. Rivastigmine is a long-acting cholinesterase inhibitor with a similar chemical structure to physostigmine. It represents a potential therapeutic option for antimuscarinic delirium. Rivastigmine offers potential benefits over physostigmine including a longer duration of action, slower rate of central nervous system penetration, more favorable side effect profile, and availability in multiple formulations. A paucity of literature exists describing the use of rivastigmine for central antimuscarinic delirium. We describe the effective use of oral rivastigmine in a child with central antimuscarinic delirium.